51366-22-4

Upstream product

• 64-17-5 ethanol 
• 7424-00-2 DL-Phe(4Cl) 
• 52031-05-7 2-amino-3-(4-chlorophenyl)propionic acid ethyl ester hydrochloride 
• 104-88-1 4-chlorobenzaldehyde 
• 6941-36-2 2-acetylamino-2-(4-chlorobenzyl)malonic acid diethyl ester 
• 23633-07-0 2-amino-3-(4-chlorophenyl)propionic acid hydrochloride 
• 84713-70-2 N-(4-chlorophenyl)methyleneglycine ethyl ester 
• 622-95-7 4-chlorobenzyl bromide 
• 69555-14-2 ethyl N-diphenylmethylene glycine 
• 104-83-6 1-Chloro-4-(chloromethyl)benzene 

Relevant academic research and scientific papers

COMPOSITIONS AND METHODS FOR CYCLOFRUCTANS AS SEPARATION AGENTS

The present invention relates to derivatized cyclofructan compounds, compositions comprising derivatized cyclofructan compounds, and methods of using compositions comprising derivatized cyclofructan compounds for chromatographic separations of chemical species, including enantiomers. Said compositions may comprise a solid support and/or polymers comprising derivatized cyclofructan compounds.

Anthranilic acid based CCK1 receptor antagonists: Preliminary investigation on their second "touch point"

In this phase of structure-affinity relationship study of VL-0395, a new anthranilic acid based CCK1 selective antagonist, we propose a series of unnatural aminoacidic derivatives. The result of this work is the identification of a new CCK ligand, which possesses an affinity (IC50 = 35 nm) one order of magnitude greater than the lead and, as a general rule, it points out how the hypothesized receptorial pocket which accommodates the Phe residue allows much more structural modification than that interacting with the N-terminal group. Hence, the modification of the C-terminal pharmacophoric group of our lead VL-0395 can not only enhance the affinity of anthranilic acid derivatives but can modulate the selectivity for one CCK receptor subtype or afford mixed antagonists.

Synthesis and antitumor activity of platinum(II) complexes containing substituted ethylenediamine ligands

The synthesis of substituted ethylenediamines, their reactions with K2PtCl4 to give the dichloroplatinum(II) complexes, and the exchange of the chloro ligands for other leaving groups are described.The new compounds have been tested as antitumor agents both in vitro using the hormone independent human mammary carcinoma cell line MDA-MB 231 as well as in vivo using the lymphocytic P388 leukemia of the CD2F1-mouse.In the P388 test, 53 of the 55 tested complexes fulfill the minimum activity of 125percent T/C required for a substance to be active.

Method of treating nausea and vomiting with certain substituted-phenylalkylamino (and aminoacid) derivatives and other serotonin depleting agents

A method for the treatment of emesis in a mammal, which method comprises administering to said mammal an emesis inhibiting amount of a compound which depletes serotonin in the brain of mammals; among which are compounds having the formula: STR1 wherein, R is selected from hydrogen, loweralkyl, trifluoromethyl, carboxyl, or loweralkoxycarbonyl; R1 and R2 are hydrogen or loweralkyl; Z is trifluoromethyl or halogen; the optical isomers and pharmaceutically acceptable salts thereof; two of the preferred compounds of the invention are fenfluramine and norfenfluramine.

SYNTHESIS OF AMINO ACIDS. ALKYLATION OF ALDIMINE AND KETIMINE DERIVATIVES OF GLYCINE ETHYL ESTER UNDER VARIOUS PHASE-TRANSFER CONDITIONS

The Schiff base derived from glycine ethyl ester and p-chlorobenzaldehyde can be alkylated by the ion-pair extraction method as well as under catalytic liquid-liquid or solid-liquid phase-transfer conditions.This imine is compared with the corresponding benzophenone Schiff base.